David Greenwald is the founder of Apertura Gene Therapy. Apertura Gene Therapy has raised $67M in total funding. Latest round: Series A.
David Greenwald, Ph.D. is the founder of Apertura Gene Therapy, a biotechnology startup launched in April 2022. The company develops genetic medicines focusing on limitations in gene delivery and expression. He secured $67 million in Series A financing from Deerfield Management Company.
Full founder directory · Investor directory · Company funding database · Fundraising library